RxDoctor Payments Data

Kasee McArthur, APRN

Family · Elk City, OKNPI 1154798759

Payments from drug & device makers

$479in general payments, 2019–2025

Across 28 payments — averaging $17.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$181
  • Novo Nordisk$73
  • Boehringer Ingelheim$61
  • Takeda Pharmaceuticals U.S.A., Inc.$41
  • Amgen$35
  • AstraZeneca$26
  • plus $64 from 4 others

What the payments were for

  • Food & beverage$479100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$479 in reported general payments places this provider in the 55th percentile of 2,026 family providers in Oklahoma.

See all family providers in Oklahoma

Medicare billing

Part B allowed, 2024
$54,666
Medicare patients
126
Services billed
1,026

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide51$88,340
JardianceEmpagliflozin22$24,828
FarxigaDapagliflozin Propanediol23$24,150
VraylarCariprazine Hcl13$21,825
TrintellixVortioxetine Hydrobromide30$18,900
LinzessLinaclotide19$17,654
Soliqua 100-33Insulin Glargine/Lixisenatide13$16,586
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$16,152
Mesalamine12$8,618
Combivent RespimatIpratropium/Albuterol Sulfate14$6,485
Omeprazole81$1,844
Levothyroxine Sodium140$1,654
Colestipol Hcl13$1,526
Bupropion XlBupropion Hcl45$1,471
Rosuvastatin Calcium95$1,435

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$13$88,34051 claims
AbbVieVraylar, Linzess$181$39,47932 claims
Boehringer IngelheimJardiance, Combivent Respimat$61$31,31336 claims
AstraZenecaFarxiga$26$24,15023 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$41$18,90030 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$11$16,58613 claims
GSKTrelegy Ellipta$26$16,15224 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,026 family providers in Oklahoma.

Other family in Elk City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →